Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2001

View Archived Issues

Immune response boosted by MVA-BN melanoma vaccine

MedImmune and Genaera establish anti-IL-9 antibody collaboration

Samaritan to acquire exclusive worldwide rights to Georgetown technologies

Gem Pharmaceuticals develops noncardiotoxic anthracycline antitumor agents

Newly synthesized cognition-enhancing agent ZSET-845 presented at Kyoto meeting

Topoisomerase I and II inhibitor conjugates jointly designed by U.S. universities

Banyu's new antidiabetic/antiobesity agents increase GLP-1 levels

Pharming acquires ProBio

Research at Ligand leads to identification of androgen receptor modulators

Nicotinic cholinergic receptor agonists selective for brain receptors discovered at Targacept

Vanderbilt researchers patent selective new adenosine A2B antagonists

Urokinase inhibitors synthesized at Abbott; compositions and methods of use described

Abbott describes use of new GR antagonists in diabetes Rx

Lion Bioscience reaches milestone in drug target alliance with Bayer

Proglutathione antioxidant with potential for reducing side effects of NRTI and in neuroAIDS Rx

Patient dosing begins in phase I trial of intravenous IL-2 gene medicine

Selective inhibitor of SGLT-2 synthesized at Kissei useful for the treatment of diabetes

Cotara enters additional trial for liver cancer

Use of cariporide in liver fibrosis discussed at EASL meeting

Low-dose Climara approved by FDA as starting dose for menopausal symptoms

Vical discontinues current Leuvectin trial in kidney cancer and plans new trial

L-dT safe and effective in patients with chronic HBV infection according to preliminary data

Potent and selective anti-HIV agents disclosed at recent Japanese scientific conference

Gastric prokinetic agents with a quinazoline structure in development at Kyowa Hakko

Naja venom fraction induces apoptosis in human leukemia cells

Singulair approved for treatment of children with asthma as young as two years

Novel memory-enhancing technology licensed by Axonyx from TJU

DuPont releases structures of new HIV protease inhibitors DPC-681, DPC-684

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...